Image source: Shutterstock

Highlights

  • Shares of Fisher & Paykel Healthcare rise 2.9% to NZ$35.43, marking their highest levels since 21 February.

  • Jefferies upgrades stock to "buy" and raises price target to NZ$39.40, citing effective mitigation of U.S. tariffs.

  • Analysts optimistic about company's inventory strategy and potential price increases to buffer tariff impacts.

Shares of New Zealand-based Fisher & Paykel Healthcare (FPH) surged as much as 2.9%, reaching NZ$35.43, their highest point since 21 February 2025. This jump follows an upgrade by analysts at Jefferies, who raised their rating for the medical equipment maker from "hold" to "buy" and increased the price target to NZ$39.40, up from NZ$35.25.

Jefferies analysts believe that Fisher & Paykel is well-positioned to manage the impact of the 25% U.S. tariffs on Mexican imports. According to their analysis, the company’s New Zealand-manufactured products are already FDA approved, giving them the flexibility to substitute Mexican imports with New Zealand imports—a shift that only faces logistical challenges like re-routing and freight lead times.

Furthermore, the company has a three-month inventory in the U.S., which, coupled with the potential for price increases, will help mitigate the tariff’s effects in FY26, analysts from Jefferies noted.

Despite the positive outlook, only two out of twelve analysts currently rate Fisher & Paykel Healthcare as a "buy," while seven have a "hold" rating, and three rate the stock at "sell" or lower. The median price target for the stock, according to LSEG data, is NZ$37.00.

Following today’s gains, Fisher & Paykel Healthcare's stock has trimmed its year-to-date losses to 7.7%.